Table 2.

Univariable and multivariable logistic regression analysis

	Univariable analysis
	RRa	95% CIb	P
Gender (Male, Female)	1.12	0.91–1.22	0.67
Age(<60, >60 years)	1.03	0.98–1.17	0.61
Intravesical instillation (immediate, maintenance)	0.98	0.89–1.78	0.27
Tumor stage (Ta, T1)	1.34	1.03–1.56	0.67
Tumor grade (G1 and G2, G3)	2.78	1.05–6.93	0.01
Concomitant CIS (No, Yes)	1.52	0.21–7.43	0.66
Tumor size (<3, >3 cm)	2.11	1.29–4.32	0.05
Multiplicity (Single, Multiple)	1.98	0.98–3.92	0.07
CLASP2 mRNA (low, high in tumor)	3.83	1.12–12.22	0.02
CLASP2 mRNA (low, high in urine)	2.71	1.09–7.77	< 0.01
E-cadherin mRNA (high, low in tumor)	2.97	1.17–9.82	0.04
E-cadherin mRNA (high, low in urine)	3.24	0.97–10.81	0.02
Vimentin mRNA (low, high in tumor)	1.24	0.78–2.87	0.32
Vimentin mRNA (low, high in urine)	1.19	0.26–4.98	0.09
	Multivariable analysisc
	RR	95% CI	P
Tumor stage (Ta, T1)	1.14	0.91–1.86	0.78
Tumor grade (G1 and G2, G3)	2.19	1.01–4.98	0.04
Tumor size (<3, >3 cm)	1.71	1.08–3.37	0.07
Intravesical instillation (immediate, maintenance)	1.12	0.79–1.45	0.52
Multiplicity (Single, Multiple)	2.32	1.18–4.22	0.18
CLASP2 mRNA (low, high in tumor)	2.76	1.02–10.11	< 0.01
CLASP2 mRNA (low, high in urine)	3.75	1.09–6.12	< 0.01
E-cadherin mRNA (high, low in tumor)	2.78	1.17–8.24	0.01
E-cadherin mRNA (high, low in urine)	3.34	1.12–7.45	0.01
Vimentin mRNA (low, high in tumor)	1.35	0.89–3.43	0.51
Vimentin mRNA (low, high in urine)	1.78	0.26–3.48	0.35

^aRelative risk

^bConfidence interval of the estimated RR

^cMultivariable analysis adjusted for tumor grade, stage, size, multiplicity, levels of CLASP2, E-cadherin and Vimentin mRNA in the tumor or urine